Minimise transmission risk of CJD and vCJD in healthcare settings

Prevention of CJD and vCJD by the Advisory Committee on Dangerous Pathogens' Transmissible Spongiform Encephalopathy (ACDP TSE) subgroup.

Applies to England



Annex A2: distribution of infectivity in animal tissue and body fluids

This file may not be suitable for users of assistive technology.

Request an accessible format.
If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email Please tell us what format you need. It will help us if you say what assistive technology you use.

Annex B: diagnostic criteria

Annex F: endoscopy

Annex H: after death

CJD guidance for ophthalmologists

Frequently asked questions




This guidance produced by the ACDP TSE risk management subgroup aims to help minimise the risk of transmission of Creutzfeldt-Jakob disease (CJD) and variant Creutzfeldt-Jakob disease (vCJD) in healthcare and other work settings.

Published 27 November 2012
Last updated 18 November 2021 + show all updates
  1. Updated part 3: 'Laboratory containment and control measures'.

  2. Added explanatory diagrams to Annex J.

  3. Added updated document: Annex F: Endoscopy.

  4. Uploaded updated versions of Annex A1, Annex F and the Acknowledgements.

  5. Sections on Infection control and annexes C and F have been updated to reflect the latest scientific research.

  6. Updated version of Annex J on Presurgical Assessment

  7. First published.